Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn’s Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199539 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anna Helmin-Basa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Farmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Crohn Disease, B-Lymphocyte Subsets, Biological Therapy. Die Arbeit nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IDUB IDE Interdisciplinary GASTRo IMMUNe Monitoring Team (GASTRIMMUN), IDUB-IDE program at Nicolaus Copernicus University in Toruń: Interdisciplinary GASTRo IMMUNe Monitoring Team.
Abstract (Originalsprache)
Biological therapies for Crohn’s disease (CD), including infliximab, adalimumab, and vedolizumab, show variable efficacy. While some predictive biomarkers exist, data on regulatory immune cells are limited. This study examined whether baseline levels of circulating T and B cell subsets can predict response to these treatments. We recruited 43 adults with conventional treatment-resistant active CD (CDAI > 330) and 16 healthy controls. Blood samples were analysed by flow cytometry at baseline (week 0) and after induction therapy (week 12 or 14, depending on the received drug) to measure T and B cell subsets and correlate them with disease activity. CD patients at baseline showed a significantly reduced frequency of memory B cells, CD5+CD1d+ B cells, plasmablasts, and transitional B cells. Additionally, significant negative correlations were identified between transitional B cells and calprotectin/platelets, and between CD5+CD1d+ B cells and calprotectin. All CD patients responded clinically to biologic therapy. In those treated with infliximab or adalimumab, mature naïve B cells decreased, with a trend toward increased CD24hiCD27+ B cells. Adalimumab responders showed a trend toward higher CD161 expression on Tregs, while vedolizumab-treated patients had a slight increase in plasmablasts. Biologic therapies in CD revealed treatment-specific immune correlations: infliximab/adalimumab responses involved B and T cell changes linked to inflammation, while VDZ response correlated with CD4+ and CD5+CD1d+ B cells. Our study suggests that infliximab/adalimumab induction therapy in CD expands circulating CD24hiCD27+ B cells and reduces mature naïve B cells, while vedolizumab increases plasmablasts. These B-cell changes may reflect distinct mechanisms and serve as potential response biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Faculty of Farmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.
- Gastroenterology Clinic, Jan Biziel University Hospital No. 2, 85-168 Bydgoszcz, Poland.
- Department of Gastroenterology and Nutrition Disorders, Faculty of Health Science, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-168 Bydgoszcz, Poland.
- Department of Microbiology and Clinical Immunology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
ORCID-Profile: Anna Helmin-Basa, Maria Kopoń, Jarosław Koza, Fabian Leśniewski, Małgorzata Wiese-Szadkowska, Jacek Michałkiewicz, Maria Kłopocka
Förderung
- IDUB IDE Interdisciplinary GASTRo IMMUNe Monitoring Team (GASTRIMMUN)
- IDUB-IDE program at Nicolaus Copernicus University in Toruń: Interdisciplinary GASTRo IMMUNe Monitoring Team
Zitieren
APA
Helmin-Basa, A., Kopoń, M., Koza, J., Strzyżewska, E., Skalska-Bugała, A., Leśniewski, F., Wiese-Szadkowska, M., Balcerowska, S., Michałkiewicz, J., & Kłopocka, M. (2025). Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199539
Vancouver
Helmin-Basa A, Kopoń M, Koza J, Strzyżewska E, Skalska-Bugała A, Leśniewski F, et al. Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn’s Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199539
BibTeX
@article{HelminBasa2025,
author = {Helmin-Basa, Anna and Kopoń, Maria and Koza, Jarosław and Strzyżewska, Edyta and Skalska-Bugała, Aleksandra and Leśniewski, Fabian and Wiese-Szadkowska, Małgorzata and Balcerowska, Sara and Michałkiewicz, Jacek and Kłopocka, Maria},
title = {Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199539}
}
EUVIMED